Result of General Meeting
Updated : 11:59
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Group" or the "Company")
Result of General Meeting
Shareholders approve capital reduction
Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound simulation and education company, announces that at the general meeting held on 15th October 2024, shareholders approved the capital reduction, the preliminary step to provide the distributable reserves required to return capital to shareholders following the sale of the Clinical AI Business to GE HealthCare for £40.5 million.
Results show that 99.99% of the shares voted (representing approximately 60% of the total shares outstanding) were in favour, with 0.01% against.
The capital reduction is expected to be confirmed by Court Order on 18th November, after which further details on the Company's plans for its Simulation Business will be announced.
For further information, please contact:
Intelligent Ultrasound Group plc | |
Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 |
Helen Jones, CFO |
|
| |
Cavendish Capital Markets Limited (Nominated advisor and broker)
|
|
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks (Life Sciences Specialist Sales) Dale Bellis (Sales) | Tel: +44 (0)20 7397 8900
|
Cardew Group - PR Advisors | |
Allison Connolly Emma Pascoe-Watson Jessica Pilling | Tel: +44 (0)7587 453955 Tel: +44 (0)7774 620415 Tel: +44 (0)7918 584573 |
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading ultrasound simulation and education companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market. The company's main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator, the new BabyWorks Neonate and Paediatric training simulator and NeedleTrainer, which teaches real-time ultrasound-guided needling. To date over 1,800 simulators have been sold to over 800 medical institutions around the world.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.